Structure of the pseudokinase-kinase domains from protein kinase TYK2 reveals a mechanism for Janus kinase (JAK) autoinhibition

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 22, 2014, Pages 8025-8030

  Lupardus, Patrick J ^a   Ultsch, Mark ^a   Wallweber, Heidi ^a   Kohli, Pawan Bir ^a   Johnson, Adam R ^a   Eigenbrot, Charles ^a  

^a GENENTECH INC   (United States)

Author keywords

JAK1; JAK3

Indexed keywords

JANUS KINASE; PHOSPHOTRANSFERASE; PROTEIN KINASE TYK2; PSEUDOKINASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; CRYSTALLIZATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME STRUCTURE; EXON; HINGE REGION; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN SECONDARY STRUCTURE;

JAK1; JAK3;

ANIMALS; CELL LINE; CRYSTALLOGRAPHY, X-RAY; DIMERIZATION; ENZYME ACTIVATION; HUMANS; INSECTS; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE 3; MUTATION; NEOPLASMS; PROTEIN STRUCTURE, TERTIARY; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP; TYK2 KINASE;

EID: 84901840527     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1401180111     Document Type: Article

References (37)

1. Leonard WJ, O'Shea JJ (1998) Jaks and STATs: Biological implications. Annu Rev Immunol 16:293-322. (Pubitemid 28183367)
2. Haan C, Kreis S, Margue C, Behrmann I (2006) Jaks and cytokine receptors - an intimate relationship. Biochem Pharmacol 72(11):1538-1546. (Pubitemid 44666728)
3. Rodig SJ, et al. (1998) Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses. Cell 93(3): 373-383. (Pubitemid 28232082)
4. Parganas E, et al. (1998) Jak2 is essential for signaling through a variety of cytokine receptors. Cell 93(3):385-395. (Pubitemid 28232083)
5. Neubauer H, et al. (1998) Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell 93(3):397-409. (Pubitemid 28232084)
6. Casanova JL, Holland SM, Notarangelo LD (2012) Inborn errors of human JAKs and STATs. Immunity 36(4):515-528.
7. Wilks AF, et al. (1991) Two novel protein-tyrosine kinases, each with a second phos-photransferase-related catalytic domain, define a new class of protein kinase. Mol Cell Biol 11(4):2057-2065. (Pubitemid 21895577)
8. Girault JA, Labesse G, Mornon JP, Callebaut I (1999) The N-termini of FAK and JAKs contain divergent band 4.1 domains. Trends Biochem Sci 24(2):54-57.
9. Saharinen P, Silvennoinen O (2002) The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction. J Biol Chem 277(49):47954-47963. (Pubitemid 36159324)
10. Saharinen P, Takaluoma K, Silvennoinen O (2000) Regulation of the Jak2 tyrosine kinase by its pseudokinase domain. Mol Cell Biol 20(10):3387-3395. (Pubitemid 30243884)
11. Bandaranayake RM, et al. (2012) Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F. Nat Struct Mol Biol 19(8):754-759.
12. Ungureanu D, et al. (2011) The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling. Nat Struct Mol Biol 18(9): 971-976.
13. Toms AV, et al. (2013) Structure of a pseudokinase-domain switch that controls oncogenic activation of Jak kinases. Nat Struct Mol Biol 20(10):1221-1223.
14. Sanz A, et al. (2011) Analysis of Jak2 catalytic function by peptide microarrays: The role of the JH2 domain and V617F mutation. PLoS One 6(4):e18522.
15. Kontzias A, Kotlyar A, Laurence A, Changelian P, O'Shea JJ (2012) Jakinibs: A new class of kinase inhibitors in cancer and autoimmune disease. Curr Opin Pharmacol 12(4):464-470.
16. Chen E, Staudt LM, Green AR (2012) Janus kinase deregulation in leukemia and lymphoma. Immunity 36(4):529-541.
17. Vainchenker W, Constantinescu SN (2013) JAK/STAT signaling in hematological malignancies. Oncogene 32(21):2601-2613.
18. Zhao L, et al. (2009) A JAK2 interdomain linker relays Epo receptor engagement signals to kinase activation. J Biol Chem 284(39):26988-26998.
19. Staerk J, Kallin A, Demoulin JB, Vainchenker W, Constantinescu SN (2005) JAK1 and Tyk2 activation by the homologous polycythemia vera JAK2 V617F mutation: Crosstalk with IGF1 receptor. J Biol Chem 280(51):41893-41899. (Pubitemid 43023158)
20. Lucet IS, et al. (2006) The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor. Blood 107(1):176-183. (Pubitemid 43053540)
21. Chrencik JE, et al. (2010) Structural and thermodynamic characterization of the TYK2 and JAK3 kinase domains in complex with CP-690550 and CMP-6. J Mol Biol 400(3): 413-433.
22. Boggon TJ, Li Y, Manley PW, Eck MJ (2005) Crystal structure of the Jak3 kinase domain in complex with a staurosporine analog. Blood 106(3):996-1002. (Pubitemid 41076445)
23. Scott LM (2011) The JAK2 exon 12 mutations: A comprehensive review. Am J Hematol 86(8):668-676.
24. Liang J, et al. (2013) Lead optimization of a 4-aminopyridine benzamide scaffold to identify potent, selective, and orally bioavailable TYK2 inhibitors. J Med Chem 56(11): 4521-4536.
25. Tsui V, et al. (2011) A new regulatory switch in a JAK protein kinase. Proteins 79(2): 393-401.
26. Flex E, et al. (2008) Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia. J Exp Med 205(4):751-758. (Pubitemid 351549874)
27. Sato T, et al. (2008) Functional analysis of JAK3 mutations in transient myeloproliferative disorder and acute megakaryoblastic leukaemia accompanying Down syndrome. Br J Haematol 141(5):681-688. (Pubitemid 351667619)
28. Bercovich D, et al. (2008) Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome. Lancet 372(9648):1484-1492.
29. Mullighan CG, et al. (2009) JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc Natl Acad Sci USA 106(23):9414-9418.
30. Kearney L, et al. (2009) Specific JAK2 mutation (JAK2R683) and multiple gene deletions in Down syndrome acute lymphoblastic leukemia. Blood 113(3):646-648.
31. Gaikwad A, et al. (2009) Prevalence and clinical correlates of JAK2 mutations in Down syndrome acute lymphoblastic leukaemia. Br J Haematol 144(6):930-932.
32. Korniski B, et al. (2010) Expression, purification, and characterization of TYK-2 kinase domain, a member of the Janus kinase family. Biochem Biophys Res Commun 396(2): 543-548.
33. Dusa A, et al. (2008) Substitution of pseudokinase domain residue Val-617 by large non-polar amino acids causes activation of JAK2. J Biol Chem 283(19):12941-12948.
34. Dusa A, Mouton C, Pecquet C, Herman M, Constantinescu SN (2010) JAK2 V617F constitutive activation requires JH2 residue F595: A pseudokinase domain target for specific inhibitors. PLoS One 5(6):e11157.
35. Boudeau J, Miranda-Saavedra D, Barton GJ, Alessi DR (2006) Emerging roles of pseudokinases. Trends Cell Biol 16(9):443-452. (Pubitemid 44293399)
36. Kershaw NJ, et al. (2013) SOCS3 binds specific receptor-JAK complexes to control cytokine signaling by direct kinase inhibition. Nat Struct Mol Biol 20(4):469-476.
37. Hall T, et al. (2010) Expression, purification, characterization and crystallization of non- and phosphorylated states of JAK2 and JAK3 kinase domain. Protein Expr Purif 69(1):54-63.